Doximity
DOCS
$21.16
-3.20%
Doximity, Inc. operates a digital platform for U.S. medical professionals in the Healthcare Information Services industry. It is a leading professional network for physicians, leveraging its exclusive user base to provide collaboration, patient care coordination, and career management tools.…
DOCS
Doximity
$21.16
Related headlines
Investment Opinion: Should I buy DOCS Today?
Based on a synthesis of the data, the objective assessment is a Hold with a speculative Buy rating for risk-tolerant investors. The severe price decline has created a valuation disconnect, with a compelling forward P/E of 14.3 based on analyst EPS estimates of $2.41. However, the intense selling pressure and lack of a clear technical reversal warrant caution. The recommendation is contingent on the investor's conviction in a growth re-acceleration and tolerance for high volatility.
Sign up to view all
DOCS 12-Month Price Forecast
The outlook is balanced but skewed with uncertainty. The base case suggests modest recovery, but the high probability of the bear case necessitates a neutral stance. Confidence is medium due to the conflicting signals between valuation support and powerful negative momentum.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Doximity's 12-month outlook, with a consensus price target around $27.51 and implied upside of +30.0% versus the current price.
Average Target
$27.51
1 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
1
covering this stock
Price Range
$17 - $28
Analyst target range
Wall Street analyst coverage consists of 11 firms, with recent actions showing a mix of 'Overweight/Buy' and 'Neutral' ratings. Specific consensus target price data is not available in the provided inputs. Analysts estimate an average EPS of $2.41 for the coming period, with a revenue estimate averaging $989.2 million.
Bulls vs Bears: DOCS Investment Factors
DOCS presents a stark dichotomy between strong underlying fundamentals and catastrophic technical performance. The company's profitability, cash flow, and balance sheet are robust, but the stock has been decimated due to growth concerns and negative momentum. The current price near 52-week lows creates a high-risk, high-potential-reward scenario.
Bullish
- Exceptional Profitability: High net margin of 33.3% and robust ROE of 20.6% indicate efficient operations.
- Strong Financial Health: Minimal debt (D/E 0.011) and high current ratio (6.97) provide significant flexibility.
- Attractive Forward Valuation: Forward P/E of 14.3 is low, suggesting potential upside if earnings meet forecasts.
- Solid Cash Flow Generation: TTM Free Cash Flow of $311.5M supports growth and shareholder returns.
Bearish
- Severe Price Downtrend: Stock down ~68% in 6 months, showing persistent and heavy selling pressure.
- Revenue Growth Deceleration: Q3 YoY revenue growth slowed to 9.8%, indicating potential market saturation.
- High Short Interest: Short ratio of 4.34 suggests significant bearish sentiment from traders.
- Elevated Trailing P/E: Trailing P/E of 48.6 is high, reflecting past earnings vs. current price decline.
DOCS Technical Analysis
The stock has experienced a severe and sustained downtrend over the past six months. The price has fallen from $71.99 in early October 2025 to $23.30 as of March 31, 2026, representing a decline of approximately 67.6% over this period. This trend indicates significant and persistent selling pressure.
Short-term performance remains deeply negative. Over the last three months, the stock is down 47.4%, and over the last month, it has declined 5.0%. The price action shows a sharp drop in early February 2026, followed by a period of consolidation at these lower levels, with no clear signs of a reversal.
The current price of $23.30 is near the bottom of its 52-week range of $21.82 to $76.51, trading only about 6.8% above the 52-week low. This positioning suggests the stock is in deeply oversold territory from a price-range perspective, though no RSI data was provided to confirm momentum-based oversold conditions.
Beta
1.42
1.42x market volatility
Max Drawdown
-71.8%
Largest decline past year
52-Week Range
$21-$77
Price range past year
Annual Return
-61.9%
Cumulative gain past year
| Period | DOCS Return | S&P 500 |
|---|---|---|
| 1m | -14.6% | +0.4% |
| 3m | -51.7% | -2.0% |
| 6m | -67.7% | +4.1% |
| 1y | -61.9% | +23.9% |
| ytd | -51.1% | -0.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DOCS Fundamental Analysis
Revenue growth has shown deceleration on a year-over-year basis. The most recent quarterly revenue of $185.1 million for Q3 2026 represents 9.8% YoY growth, a slowdown compared to stronger growth in prior periods. Profitability remains robust with a net margin of 33.3% for the quarter, though this is down from a net margin of 44.6% in the year-ago quarter, indicating some margin compression.
The company exhibits exceptional financial health with a very low debt-to-equity ratio of 0.011 and a strong current ratio of 6.97. Cash flow generation is solid, with free cash flow over the trailing twelve months reported at $311.5 million, providing ample liquidity and financial flexibility.
Operational efficiency metrics are strong, with a Return on Equity (ROE) of 20.6% and a Return on Assets (ROA) of 12.8%. These figures indicate effective use of shareholder capital and company assets to generate profits, though they have moderated from higher levels seen in previous quarters.
Quarterly Revenue
$185053000.0B
2025-12
Revenue YoY Growth
+0.09%
YoY Comparison
Gross Margin
+0.89%
Latest Quarter
Free Cash Flow
$311547000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DOCS Overvalued?
Given the company's positive net income, the primary valuation metric is the Price-to-Earnings (P/E) ratio. The trailing P/E ratio is elevated at 48.6, while the forward P/E based on estimated earnings is significantly lower at 14.3. This discrepancy suggests the market is pricing in a substantial recovery in earnings growth.
Peer comparison data for industry averages is not available in the provided inputs. Therefore, a relative valuation against sector benchmarks cannot be performed. The high trailing P/E reflects the recent sharp decline in stock price against still-positive earnings, while the lower forward P/E indicates analyst expectations for improved profitability.
PE
48.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 27x~112x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
44.2x
Enterprise Value Multiple
Investment Risk Disclosure
The primary risk is the continuation of the severe downtrend, driven by decelerating revenue growth (9.8% YoY in Q3) and margin compression. The high short ratio (4.34) and beta (1.44) indicate the stock is volatile and subject to amplified negative sentiment. A key business risk is the potential saturation of its core physician network, limiting future user and revenue growth. Furthermore, the elevated trailing valuation multiples (P/E 48.6, P/S 19.0) leave the stock vulnerable to multiple compression if growth does not re-accelerate to justify the premium. The lack of a dividend and high reliance on stock price appreciation for returns adds to the risk profile in a bearish market environment.
FAQ
The key risks are: 1) Continued deceleration in revenue growth below current ~10% levels, 2) Further compression of the high net margin (33.3%), 3) Sustained negative technical momentum with the stock near its 52-week low, and 4) High short interest (ratio 4.34) that can exacerbate downward moves. The stock's high beta (1.44) also means it will likely fall more than the market in a downturn.
The 12-month forecast is a wide range due to high uncertainty. The base case target is $28-$35, assuming the company meets analyst EPS estimates of $2.41 and the forward P/E holds. The bull case sees a rally to $45-$55 on growth re-acceleration, while the bear case could see a retest of the 52-week low near $20-$24 if growth disappoints further.
DOCS sends mixed valuation signals. It appears overvalued based on trailing metrics (P/E of 48.6, P/S of 19.0), which reflect past earnings against a plummeting stock price. However, it appears undervalued on a forward-looking basis, with a forward P/E of 14.3 suggesting the market has priced in significant pessimism. The valuation hinges entirely on the company's ability to meet or exceed future earnings expectations.
DOCS is a speculative buy for risk-tolerant investors seeking a turnaround. The stock is deeply oversold, down ~68% in six months, and trades at a reasonable forward P/E of 14.3 based on estimated EPS of $2.41. However, it is not a good buy for conservative investors, given the severe downtrend, high short interest, and decelerating revenue growth, which require a strong stomach for volatility.
DOCS is more suitable for a long-term investment horizon (3+ years) for investors who believe in the durability of its physician network platform. The current volatility and lack of a clear bottom make it very risky for short-term trading. Long-term holders can potentially benefit from a valuation recovery if the company's fundamentals remain strong, but they must withstand significant near-term pain.